MyMD Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Intangible Assets (Tables)

Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets

Intangible assets as of December 31, 2015 and 2014 and the movements for the years then ended are as follows:

						Distributor &
		Patents &				Customer
		Trademarks				Relationships				Totals
*Cost or Deemed Cost*
At December 31, 2013		$	3,851,494			$	1,270,639			$	5,122,133
Additions			-				-				-
Disposal			-				-				-
At December 31, 2014		$	3,851,494			$	1,270,639			$	5,122,133

*Accumulated Amortization*
At December 31, 2013		$	1,416,857			$	1,270,639			$	2,687,496
Amortization Charge			258,572				-				258,572
Disposal			-				-				-
At December 31, 2014		$	1,675,429			$	1,270,639			$	2,946,068

*Net Book Value*
At December 31, 2013		$	2,434,637			$	-			$	2,434,637
At December 31, 2014		$	2,176,065			$	-			$	2,176,065

*Cost or Deemed Cost*
At December 31, 2014		$	3,851,495			$	1,270,639			$	5,122,134
Additions			-				-				-
Disposal			(1,224,499	)			-				(1,224,499	)
At December 31, 2015		$	2,626,996			$	1,270,639			$	3,897,635

*Accumulated Amortization*
At December 31, 2014		$	1,675,430			$	1,270,639			$	2,946,069
Amortization Charge			236,706				-				236,706
Disposal			(758,023	)			-				(758,023	)
At December 31, 2015		$	1,154,113			$	1,270,639			$	2,424,752

*Net Book Value*
At December 31, 2014		$	2,176,065			$	-			$	2,176,065
At December 31, 2015		$	1,472,883			$	-			$	1,472,883

Schedule of Estimated Aggregate Amortization Expense of Fiscal Years

The estimated aggregate amortization expense for each of the five succeeding fiscal years is as follows:

Period		Amount
2016		$	171,108
2017		$	171,108
2018		$	171,108
2019		$	171,108
2020		$	171,108